3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
4
Unknown
1
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
412
Carcinoma, Non-Small-Cell Lung
285
Prostatic Neoplasms
208
Neoplasms
202
Neoplasm Metastasis
179
Melanoma
164
Multiple Myeloma
158
Colorectal Neoplasms
157
Leukemia, Myeloid, Acute
143
Lung Neoplasms
132
Leukemia
126
Lymphoma
118
Pancreatic Neoplasms
117
Recurrence
111
Ovarian Neoplasms
111
Leukemia, Lymphocytic, Chronic, B-Cell
110
Lymphoma, Non-Hodgkin
104
Carcinoma, Renal Cell
104
Brain Neoplasms
89
Myelodysplastic Syndromes
88
Precursor Cell Lymphoblastic Leukemia-Lymphoma
86
Glioblastoma
84
Lymphoma, Large B-Cell, Diffuse
80
Lymphoma, Follicular
79
Carcinoma, Hepatocellular
79
Head and Neck Neoplasms
77
Squamous Cell Carcinoma of Head and Neck
76
Urinary Bladder Neoplasms
66
Stomach Neoplasms
61
Hodgkin Disease
59
Interventions
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Terminated
×
Neoplasms, Second Primary
×
Clear all
NCT00638963
2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2
Terminated
6 enrolled
9 charts